Evaluation of a pharmacist-managed amiodarone monitoring program

Journal of Managed Care Pharmacy

Volumn 17, Issue 7, 2011, Pages 513-522

  Spence, Michele M ^a   Polzin, Jennifer K ^b   Weisberger, Calvin L ^a   Martin, John P ^a   Rho, Jay P ^a   Willick, Giselle H ^a  

^a KAISER PERMANENTE   (United States)

^b Ambulatory Care Pharmacy   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMIODARONE; ATORVASTATIN; CARBON MONOXIDE; DIGOXIN; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; THYROTROPIN; THYROXINE;

ABNORMAL LABORATORY RESULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; COHORT ANALYSIS; COMORBIDITY; DRUG MEGADOSE; DRUG MONITORING; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW UP; FREE THYROXINE INDEX; HEALTH CARE MANAGEMENT; HEALTH CARE QUALITY; HEALTH PROGRAM; HOSPITALIZATION; HUMAN; INTERSTITIAL LUNG DISEASE; LIVER FUNCTION; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; PHARMACIST; PHARMACIST MANAGED AMIODARONE MONITORING PROGRAM; PRESCRIPTION; RETROSPECTIVE STUDY; RHABDOMYOLYSIS; THORAX RADIOGRAPHY; THYROID FUNCTION; THYROID GLAND; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL;

EID: 84863080512     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2011.17.7.513     Document Type: Article

References (23)

1. Cordarone (amiodarone HCL) tablets. Wyeth Pharmaceuticals. December 2010. Available at: http://labeling.pfizer.com/showlabeling.aspx?id=93. Accessed August 23, 2011.
2. Zimetbaum P, Ho KKL, Olshansky B, et al.; FRACTAL Investigators. Variation in the utilization of antiarrhythmic drugs in patients with newonset atrial fibrillation. Am J Cardiol. 2003;91(1):81-83.
3. Siddoway LA. Amiodarone: guidelines for use and monitoring. Am Fam Physician. 2003;68(11):2189-96. Available at: http://www.aafp.org/afp/2003/1201/p2189.html. Accessed August 23, 2011.
4. No authors listed. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Lancet. 1997;350(9089):1417-29.
5. Hilleman D, Miller MA, Parker R, Doering P, Pieper JA. Optimal management of amiodarone therapy: efficacy and side effects. Pharmacotherapy. 1998;18(6 Pt 2):138S-145S.
6. Vorperian VR, Havighurst TC, Miller S, January CT. Adverse effects of low dose amiodarone: a meta-analysis. J Am Coll Cardiol. 1997;30(3):791-98.
7. Dusman R, Stanton MS, Miles WM, et al. Clinical features of amiodaroneinduced pulmonary toxicity. Circulation. 1990;82(1):51-59.
8. U.S. Food and Drug Administration. Interaction between amiodarone (marketed as CORDARONE and PACERONE) and simvastation (marked as ZOCOR and generics) or simvastation-combination products (marketed as VYTORIN and SIMCOR). Amiodarone potentiates the risk for simvastation-associated rhabdomyolysis. Postmarketing Reviews, vol. 1, no. 1. Summer 2008. Available at: http://www.fda.gov/Drugs/DrugSafety/DrugSafetyNewsletter/ucm120613.htm#amiodarone_simvastatin. Accessed August 23, 2011
9. Goldschlager N, Epstein AE, Naccarelli GV, et al.; the Practice Guidelines Subcommittee and the North American Society of Pacing and Electrophysiology. A practical guide for clinicians who treat patients with amiodarone: 2007. Heart Rhythm. 2007;4(9):1250-59.
10. Raebel MA, Carroll NM, Simon SR, et al. Liver and thyroid monitoring in ambulatory patients prescribed amiodarone in 10 HMOs. J Manag Care Pharm. 2006;12(8):656-64. Available at: http://amcp.org/data/jmcp/656-664.pdf.
11. Bickford CL, Spencer, AP. Adherence to the NASPE guideline for amiodarone monitoring at a medical university. J Manag Care Pharm. 2006;12(3):254-59. Available at: http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=7351.
12. Tjia J, Field TS, Garber LD, et al. Development and pilot testing of guidelines to monitor high-risk medications in the ambulatory setting. Am J Manag Care. 2010;16(7):489-96.
13. Johnson SG. Improving cost-effectiveness of and outcomes from drug therapy in patients with atrial fibrillation in managed care: role of the pharmacist. J Manag Care Pharm. 2009;15(6 Suppl B):19S-25S. Available at: http://www.amcp.org/data/jmcp/1003.19-25.pdf.
14. Johnson SG, Canty K, Billups S, Schimmer J. Adherence to amiodarone monitoring recommendations before and after implementation of a centralized pharmacy service: a cohort study. J Pharm Pract. 2010;23(6):536-39.
15. Graham MR, Wright MA, Manley HJ. Effectiveness of an amiodarone protocol and management clinic in improving adherence to amiodarone monitoring guidelines. J Pharm Technol. 2004;20:5-10. Available at: http://jpharmtechnol.com/abstracts/volume20/January-February/5.html. Accessed August 23, 2011.
16. Raebel MA, Lyons EE, Chester EA, et al. Improving laboratory monitoring at initiation of drug therapy in ambulatory care. Arch Intern Med. 2005;165(20):2395-401. Available at: http://archinte.ama-assn.org/cgi/content/full/165/20/2395. Accessed August 23, 2011.
17. Snider M, Kalbfleisch S, Carnes CA. Initial experience with antiarrhythmic medication monitoring by clinical pharmacists in an outpatient setting: a retrospective review. Clin Ther. 2009;31(6):1209-18.
18. Sanoski CA, Schoen MD, Gonzalez RC et al. Rationale, development, and clinical outcomes of a multidisciplinary amiodarone clinic. Pharmacotherapy. 1998;18(6 Pt 2):146S-151S.
19. Solberg LI, Hurley JS, Roberts MH, et al. Measuring patient safety in ambulatory care: potential for identifying medical group drug-drug interaction rates using claims data. Am J Manag Care. 2004;10(11 Pt 1):753-59.
20. Ash AS, Ellis RP, Pope GC, et al. Using diagnoses to describe populations and predict costs. Health Care Financ Rev. 2000;21(3):7-28. Available at: http://www.cms.gov/HealthCareFinancingReview/Downloads/00springpg7.pdf. Accessed August 23, 2011.
21. Karimi S, Hough A, Beckey C, Parra D. Results of a safety initiative for patients on concomitant amiodarone and simvastatin therapy in a Veterans Affairs medical center. J Manag Care Pharm. 2010;16(7):472-81. Available at: http://www.amcp.org/data/jmcp/472-481.pdf.
22. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA. 2003;289(13):1681-90.
23. Perez A, Doloresco F, Hoffman JM, et al. Economic evaluations of clinical pharmacy services: 2001-2005. Pharmacotherapy. 2009;29(1):128.